168,400
-16.01%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alteogen
Its shares trade on KOSDAQ under the ticker 196170.KQ. It has been listed since 12 December 2014. In the fiscal year to 31 December 2025, it reported revenue of ₩215.86bn and net income of ₩141.67bn. At that date it held total assets of ₩698.74bn and shareholders' equity of ₩445.19bn.
Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2014-12-12. The firm operates biobetter business segment, which develops protein pharmaceuticals and cancer therapies, and bio similar business segment, which develops bio similar and animal medicines. The firm mainly provides growth hormone, herceptin, humira, antibodies, animal drugs and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Dec 2014
- Website
- alteogen.com ↗
Leadership
Pay as last reported
- Mr. Sun Jae ParkChief Executive Officer, Director
- Mr. Hang Yeon KimChief Financial Officer, Vice President, Director, since 2022
- Mr. Tae Yeon JeonChief Administrative Officer, Vice President, Director, since 2020
- Mr. Yong Hyeon ChoVice President
- Mr. Gyeong Hui JungManaging Director
- Mr. Gyu Wan KimManaging Director
- Mr. Byeong Gyu LeeInternal Auditor
- Mr. Jeong Min LeeInternal Auditor
- Mr. Sang Rak ChoiDirector
- Mr. Yin Yeong GohNon-Executive Independent Director
- Mr. Sang Cheol LeeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 26
- Social
- 48
- Governance
- 15
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alteogen Inc develops protein pharmaceuticals and cancer therapies in Daejeon, South Korea.
- The company's biobetter business segment focuses on growth hormone and herceptin products.
- Alteogen Inc operates in the Health Care sector with a strong biotechnology industry presence.
Weaknesses
- Alteogen Inc's IPO was on 12 December 2014, which may indicate limited market history.
- The company's business segments are concentrated in biobetter and bio similar areas.
- Alteogen Inc's product range includes antibodies and animal drugs, which may have limited market reach.
Opportunities
- Alteogen Inc can expand its biobetter business segment in the Health Care sector.
- The company may leverage its bio similar business segment for animal medicine growth.
- Alteogen Inc can target the Korean market for growth hormone and herceptin products.
Threats
- Alteogen Inc faces competition from other biotechnology firms in South Korea.
- The company's reliance on specific products like herceptin may pose market risks.
- Alteogen Inc's limited IPO history could affect investor confidence in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.